Verastem Inc. (2VS)
Summary
2VS Chart
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
Verastem NASDAQ: VSTM presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer. The company also outlined plans for registrational Phase II studies and frontline Phase III trials.
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?
The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Verastem Inc. (2VS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Verastem Inc. ever had a stock split?
Verastem Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daniel W. Paterson CEO | XSTU Exchange | 92337C203 CUSIP |
| US Country | 102 Employees | - Last Dividend | 1 Jun 2023 Last Split | 27 Jan 2012 IPO Date |
Overview
Verastem, Inc. is a pioneering biopharmaceutical company engaged in the development and commercialization of novel therapeutics aimed at the treatment of cancer. Incorporated in 2010, the company dedicates its efforts to advancing cancer treatment through its innovative drug development programs. Verastem's strategic approach is characterized by a focus on targeting the essential pathways that cancer cells utilize for growth and survival. By forming key partnerships and licensing agreements with industry leaders, Verastem enhances its capacity to bring groundbreaking treatments to patients in need. The company's headquarters are located in Needham, Massachusetts, signifying a prominent presence in one of the leading biotech hubs in the United States.
Products and Services
- VS-6766
- RAMP 201 Trial
- RAMP 202 Trial
- Partnerships and Collaborations
VS-6766 operates as a novel treatment mechanism by being a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp. This innovative clamp works by interfering with MEK kinase activity and preventing RAF from phosphorylating MEK. By targeting this specific pathway, VS-6766 aims to disrupt the growth and survival mechanisms of cancer cells, holding promise as a potent cancer therapeutic.
The RAMP 201 trial is an adaptive, two-part multicenter, parallel cohort, randomized open-label study focused on evaluating the efficacy and safety of avutometinib alone, and in combination with defactinib, a focal adhesion kinase (FAK) inhibitor. This clinical trial specifically targets patients with recurrent low-grade serous ovarian cancer, exploring new avenues for treatment and potentially offering new hope to this patient population.
RAMP 202 enters the Phase 2 trial stage, assessing the safety and effectiveness of VS-6766 in combination with defactinib among patients afflicted with KRAS and BRAF mutant non-small cell lung cancer. This trial notably follows patients who have previously undergone treatment with a platinum-based regimen and an immune checkpoint inhibitor, seeking to identify more effective treatment protocols for this challenging patient group.
Verastem, Inc. has established significant partnerships to further its research and development endeavors. This includes a license agreement with Chugai Pharmaceutical Co., Ltd., focusing on the development, commercialization, and manufacture of products containing avutometinib. Additionally, a collaboration with Pfizer Inc. is aimed at the research, development, manufacture, and commercialization of Pfizer's focal adhesion kinase (FAK) inhibitors for various uses in humans. Verastem also engages in a clinical collaboration with Amgen, Inc. to explore the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM in the RAMP 203 trial. Furthermore, a discovery and development collaboration with GenFleet Therapeutics is geared towards advancing new treatment programs targeting RAS pathway-driven cancers, marking Verastem's commitment to combating cancer on multiple fronts.
Contact Information
